Stryker announced its agreement to acquire Amplitude Vascular Systems (AVS), a firm specializing in intravascular lithotripsy (IVL) for treating artery disease, though the financial terms were not disclosed. The acquisition aims to strengthen Stryker's peripheral vascular portfolio with AVS's Pulse IVL system, which is seen as a potential challenger to existing IVL technologies by competitors like Johnson & Johnson and Boston Scientific. This move highlights Stryker's increasing focus on cardiovascular treatments and high-growth markets through strategic acquisitions.

This article features a video from Huntington Bank discussing "The Three Things We Learned This Week" which is a regular blog post from Huntington officials. In this week's video, Randy Hare, Director of Equity Research at Huntington Bank, analyzes market and economy insights, covering volatility across three key markets. He also shares findings on new personal spending and income data, and discusses how market stability is being rewarded beyond just mega-cap stocks.

Oppenheimer has upgraded Blackstone (BX) stock to Outperform, citing its status as a "premier franchise" available at an attractive valuation. Despite a recent 25% year-to-date pullback, Blackstone's fundamentals remain strong with significant revenue and net income growth in 2025, and robust inflows. The upgrade, supported by a $154 price target, suggests that recent market "dislocation" does not reflect the company's underlying health and growth potential.

CMS Energy (CMS) is projected to beat its upcoming earnings estimates, continuing a trend from its previous two reports. The company has a positive Earnings ESP of +10.35% and a Zacks Rank #2 (Buy), indicating a high probability of exceeding expectations. Investors should consider these factors ahead of its next earnings release scheduled for April 28, 2026.

Textron Aviation Defense LLC, a subsidiary of Textron Inc., has secured a five-year U.S. government contract worth over $150 million to provide engineering and program management services for the T-6A, T-6B, and T-6D aircraft fleets used by the U.S. Air Force, Navy, and Army. This contract extends existing services for an additional five years, increasing the total cumulative contract ceiling to $510 million. The company's stock currently trades below its fair value, indicating a potentially undervalued opportunity in the aerospace sector.

Halliburton Co. has secured a multibillion-dollar, multi-year contract from Argentina's state-run oil company YPF. Under this agreement, Halliburton will exclusively provide bundled fracking services in the Vaca Muerta shale patch, marking the international debut of its Zeus electric-powered fracturing technology.

Caterpillar Inc. (CAT) has maintained its quarterly dividend at $1.51 per share, continuing an impressive streak of 32 consecutive years of dividend increases, solidifying its status as an S&P 500 Dividend Aristocrat. Despite a period of declining revenues, the company raised its dividend in the past, demonstrating confidence in its long-term financial health. With improving operational momentum, record backlogs, and favorable market trends, Caterpillar is well-positioned for another potential dividend hike in the near future.

Chipotle Mexican Grill is set to open a new restaurant in Melbourne, Florida, on April 14, 2026. Located at 4521 Andromeda Road, this new establishment will feature a drive-thru pickup lane and will be open daily from 10:45 a.m. to 10 p.m. This expansion is part of Chipotle's strategy to increase its presence in Brevard County, capitalizing on the growing demand for fast-casual dining and quality Mexican cuisine.

Lowey Dannenberg P.C. has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio materially overstated the capabilities of its product, Anktiva, leading to significant investor losses. Investors who lost over $100,000 are encouraged to contact the firm, with a deadline of May 26, 2026, to serve as Lead Plaintiff.

Thermo Fisher Scientific's PPD clinical research business has announced a strategic collaboration with HealthVerity to significantly expand its real-world data (RWD) capabilities. This agreement provides enterprise-level access to HealthVerity’s TaXOnomy claims dataset, covering over 270 million de-identified U.S. patient lives, and a marketplace of additional curated data sources. The collaboration aims to enhance data-driven clinical development, optimize trial feasibility and recruitment, and strengthen real-world evidence generation for biopharma sponsors.